Bionic pancreas improves type 1 diabetes management compared to standard insulin delivery methods


Health News-A device known as a bionic pancreas, which uses next-generation technology to automatically deliver insulin, was more effective at maintaining blood glucose (sugar) levels within the normal range than standard-of-care management among people with type 1 diabetes, a new multicenter clinical trial has found. 

The trial was primarily funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health, and published in the New England Journal of Medicine(link is external).

Automated insulin delivery systems, also called artificial pancreas or closed-loop control systems, track a person’s blood glucose levels using a continuous glucose monitor and automatically deliver the hormone insulin when needed using an insulin pump. These systems replace reliance on testing glucose levels by fingerstick, continuous glucose monitor with separate insulin delivery through multiple daily injections, or a pump without automation.

To learn more visit:

Photo credit: NIH

This article was shared by the National Institutes of Health and has not been revised.

Learn more about supporting The Los Angeles News by visiting

I'm interested
I disagree with this
This is unverified